Prime Medicine Inc. is a biotechnology company that leverages its proprietary Prime Editing platform to develop a new class of differentiated genetic therapies. The company's technology acts as a DNA word processor, designed to "search and replace" disease-causing genetic sequences at their precise location in the genome without causing double-strand DNA breaks. Headquartered in Cambridge, Massachusetts, Prime Medicine focuses on high-value programs across core areas including hematology, immunology, oncology, and liver diseases. Its pipeline includes ex vivo hematopoietic stem cell programs for chronic granulomatous disease (CGD) and in vivo lipid nanoparticle programs for Wilson's disease and alpha-1 antitrypsin deficiency (AATD). By addressing diseases driven by defined genetic alterations, the company aims to provide durable and potentially curative treatment options for patients.
